Drug intelligence / Profile preview

ZP-1

Development stage: Preclinical
Lead developer: Ceva Santé Animale
Modality: Peptides
Administration: Ophthalmic

Overview

ZP-1 is a peptide-based epithelial sodium channel (ENaC) inhibitor developed for veterinary use. It is intended to treat ocular surface diseases characterized by a lack of surface hydration, such as keratoconjunctivitis sicca (KCS), commonly known as dry eye, in dogs. The drug was originally discovered by Parion Sciences, licensed to Zoion Pharma for veterinary applications, and subsequently, Ceva Santé Animale acquired worldwide development and commercial rights. ZP-1 had successfully completed a proof-of-concept clinical trial in canine KCS at the time of the licensing agreement with Ceva.

Targets

ENaC

Beyond the preview

Go deeper on ZP-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZP-1.

Explore the full profile